Nir Lipsman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Recognitions
Nir Lipsman has a total of 233 co-authors. Here are the top co-authors by number of shared publications:
Ying Meng
University of Toronto
24 shared publicationsClement Hamani
Harquail Centre for Neuromodulation, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada; Division of Neurosurgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
22 shared publicationsBenjamin Davidson
19 shared publicationsPeter Giacobbe
Harquail Centre for Neuromodulation, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada; Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
18 shared publications- Andres M. Lozano
University Health Network and University of Toronto
13 shared publications Kullervo Hynynen
Harquail Centre for Neuromodulation, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada; Sunnybrook Research Institute, Toronto, ON, Canada; Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
13 shared publications
Latest Publications
- 12 November 2026
- Published by Springer Nature in Nature Mental Health
A decision-making framework for neuromodulation modalities in psychiatric disorders
- 12 November 2026
- Published by Springer Nature in Nature Mental Health
A decision-making framework for neuromodulation modalities in psychiatric disorders
- Open Access
- 25 June 2026
- Published by S. Karger AG in Stereotactic and Functional Neurosurgery
- p. 1-10
Successful MRgFUS VIM Thalamotomy for essential tremor nearby cavernous malformation: image case report
Introduction: Essential tremor (ET) is the most common movement disorder, whose severe and refractory cases may benefit from neurosurgical interventions such as Magnetic Resonance-guided Focused Ultrasound (MRgFUS) thalamotomy. Cerebrovascular diseases are generally considered a contraindication for MRgFUS due to concerns of intracerebral hemorrhage; however, they are a heterogenous group of lesions, with distinct clinical behaviors. We present the first reported case of successful MRgFUS-thalamotomy for ET in a patient with a contralateral thalamic cerebral cavernous malformation (CCM). Case Presentation: A 78-year-old male with refractory bilateral upper limb postural/action tremor was consented and planned for a left-sided ventral intermediate nucleus (VIM) MRgFUS-thalamotomy. However, brain MRI revealed a right anterior thalamic CCM measuring 1.5 cm. After careful planning, a modified treatment was still carried out – by blocking ultrasound trajectories intersecting the CCM (as well as calcifications), using increased low-medium power to avoid cavitation, and applying relatively long durations to reach the required energy (eight sonications targeting 50–55°C). The patient experienced no adverse effects, demonstrated significant tremor improvement, and postoperative imaging confirmed a well-defined lesion without complications. Discussion: The distinct histopathological features of CCMs, including slow flow and absence of arterial feeders, produce a more favorable profile compared to other cerebrovascular lesions. However, low blood flow may pose a higher risk during thermal ablation, therefore avoidance of direct ultrasound trajectories through the malformation, use of conservative temperatures, and continuous clinical monitoring were critical to ensuring procedural safety and efficacy. This case demonstrates the feasibility of MRgFUS-thalamotomy in carefully selected patients with coexisting CCMs.
- 25 June 2026
- Published by S. Karger AG in Stereotactic and Functional Neurosurgery
- p. 1-10
Open AccessSuccessful MRgFUS VIM Thalamotomy for essential tremor nearby cavernous malformation: image case report
Introduction: Essential tremor (ET) is the most common movement disorder, whose severe and refractory cases may benefit from neurosurgical interventions such as Magnetic Resonance-guided Focused Ultrasound (MRgFUS) thalamotomy. Cerebrovascular diseases are generally considered a contraindication for MRgFUS due to concerns of intracerebral hemorrhage; however, they are a heterogenous group of lesions, with distinct clinical behaviors. We present the first reported case of successful MRgFUS-thalamotomy for ET in a patient with a contralateral thalamic cerebral cavernous malformation (CCM). Case Presentation: A 78-year-old male with refractory bilateral upper limb postural/action tremor was consented and planned for a left-sided ventral intermediate nucleus (VIM) MRgFUS-thalamotomy. However, brain MRI revealed a right anterior thalamic CCM measuring 1.5 cm. After careful planning, a modified treatment was still carried out – by blocking ultrasound trajectories intersecting the CCM (as well as calcifications), using increased low-medium power to avoid cavitation, and applying relatively long durations to reach the required energy (eight sonications targeting 50–55°C). The patient experienced no adverse effects, demonstrated significant tremor improvement, and postoperative imaging confirmed a well-defined lesion without complications. Discussion: The distinct histopathological features of CCMs, including slow flow and absence of arterial feeders, produce a more favorable profile compared to other cerebrovascular lesions. However, low blood flow may pose a higher risk during thermal ablation, therefore avoidance of direct ultrasound trajectories through the malformation, use of conservative temperatures, and continuous clinical monitoring were critical to ensuring procedural safety and efficacy. This case demonstrates the feasibility of MRgFUS-thalamotomy in carefully selected patients with coexisting CCMs.
- Open Access
- 11 June 2026
- Published by Springer Nature in Research Square
The Hybrid Mind: A Mixed-Methods Multisite Study on User Experiences and Ethical Challenges of Neurotechnologies
Advances in Artificial Intelligence (AI) and neurotechnology are transforming how neural activity can be modulated and monitored to alter cognition, emotion, and behavior. Neurostimulation systems such as Deep Brain Stimulation (DBS) and repetitive transcranial magnetic stimulation (rTMS) are established interventions in neuropsychiatric care. Yet, the behavioral-psychological consequences of using these technologies remain poorly understood. We report the largest multi-center, mixed-methods study on user perceptions of neurotechnology, involving 61 DBS/rTMS users in Canada, Germany, and Switzerland. Combining surveys with in-depth interviews, we examined usability, ethical attitudes, and psychological effects, including device ownership, human-machine integration, and data concerns. DBS users more often viewed the device as part of their body and associated it with greater freedom of action and functional dependence. Across groups, participants rejected the view that neurotechnology diminished responsibility and reported lower privacy concerns when clinical benefit was evident. These insights support ethically grounded, user-centered neurotechnology development and regulation.
- 11 June 2026
- Published by Springer Nature in Research Square
Open AccessThe Hybrid Mind: A Mixed-Methods Multisite Study on User Experiences and Ethical Challenges of Neurotechnologies
Advances in Artificial Intelligence (AI) and neurotechnology are transforming how neural activity can be modulated and monitored to alter cognition, emotion, and behavior. Neurostimulation systems such as Deep Brain Stimulation (DBS) and repetitive transcranial magnetic stimulation (rTMS) are established interventions in neuropsychiatric care. Yet, the behavioral-psychological consequences of using these technologies remain poorly understood. We report the largest multi-center, mixed-methods study on user perceptions of neurotechnology, involving 61 DBS/rTMS users in Canada, Germany, and Switzerland. Combining surveys with in-depth interviews, we examined usability, ethical attitudes, and psychological effects, including device ownership, human-machine integration, and data concerns. DBS users more often viewed the device as part of their body and associated it with greater freedom of action and functional dependence. Across groups, participants rejected the view that neurotechnology diminished responsibility and reported lower privacy concerns when clinical benefit was evident. These insights support ethically grounded, user-centered neurotechnology development and regulation.
- Open Access
- 3 June 2026
- Published by Elsevier in Biological Psychiatry
Focused ultrasound ablation for psychiatric disorders
- 3 June 2026
- Published by Elsevier in Biological Psychiatry
Open AccessFocused ultrasound ablation for psychiatric disorders
- Open Access
Assessing the clinical effects of accelerated iTBS across the spectrum of treatment-resistant depression: Clinical outcomes of the PRISM-UTRD trial
Importance: Conventional repetitive transcranial magnetic stimulation (rTMS) can be ineffective in individuals who have previously failed brain stimulation, ketamine and/or multiple lines of therapies. Modern accelerated rTMS protocols using image-guided targets have not been systematically investigated in these individuals. The goal of this study was to assess the feasibility and efficacy of personalized, connectivity-guided, accelerated intermittent theta-burst stimulation (iTBS) in patients with treatment-resistant depression (TRD) of varying refractoriness. Objective: To assess whether connectivity-guided, accelerated iTBS produces significant reductions in depression severity, and to what extent this benefit extends to ultra treatment-resistant depression (UTRD). Design: This was an open-label feasibility trial of connectivity-guided, accelerated iTBS in patients with TRD. Two distinct groups of participants were recruited from a neurosurgical-psychiatry clinic with UTRD and an interventional psychiatry clinic with TRD. Patients were stratified into a priori treatment-resistance subgroups. Patients received five days of open-label treatment. Outcome measures were collected immediately prior to and after treatment, as well as at 4- and 12-weeks post-treatment. Setting: This trial ( NCT05813093 ) was conducted between November 2023 and July 2025 at Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada. Participants: Patients with major depressive disorder. A total of 96 participants were screened, with 73 meeting eligibility criteria (UTRD=30, TRD=43). One withdrew due to inability to tolerate the baseline MRI, and the other withdrew voluntarily prior to treatment. Intervention: Participants underwent a neuronavigated accelerated iTBS (600 pulses) protocol using personalized left dorsolateral prefrontal cortex (dlPFC) targets derived from functional magnetic resonance imaging (fMRI), comprising eight daily treatments, repeated over five days. Main Outcomes: Primary outcomes were i) change in Hamilton Depression Rating Scale (HAM-D17) from baseline to the end of the fifth day of treatment, and ii) the difference in change in HAM-D17 between UTRD and TRD subgroups. Results: Connectivity-guided fMRI targeting yielded personalized targets clustered around the anterolateral dlPFC. Accelerated iTBS elicited rapid antidepressant effects (ΔHAM-D17 -9.01 [SD 6.06], t = -12.45, p < 0.001) regardless of treatment-resistance group (ΔHAM-D17 -9.64 [SD 5.94] vs -8.10 [SD 6.12], t = -1.05, p = 0.299), which were sustained up to 12 weeks after treatment. Overall response and remission rates at the end of treatment were 40.8% and 16.9%. Self-report scales revealed broad symptomatic relief outside of core depressive symptoms. Conclusions & Relevance: This study demonstrated that fMRI connectivity-guided, accelerated iTBS induces sustained antidepressant effects and broader psychiatric benefits in patients across the spectrum of TRD. In a cohort unlikely to respond to most antidepressant therapies, connectivity-guided, accelerated iTBS offers a safe, well-tolerated option that can achieve benefit, or when ineffective, allow patients to expeditiously proceed with subsequent therapies than conventional rTMS. Trial Registration: This clinical trial was registered at clinicaltrials.gov with NCT05813093 .
Open AccessAssessing the clinical effects of accelerated iTBS across the spectrum of treatment-resistant depression: Clinical outcomes of the PRISM-UTRD trial
Importance: Conventional repetitive transcranial magnetic stimulation (rTMS) can be ineffective in individuals who have previously failed brain stimulation, ketamine and/or multiple lines of therapies. Modern accelerated rTMS protocols using image-guided targets have not been systematically investigated in these individuals. The goal of this study was to assess the feasibility and efficacy of personalized, connectivity-guided, accelerated intermittent theta-burst stimulation (iTBS) in patients with treatment-resistant depression (TRD) of varying refractoriness. Objective: To assess whether connectivity-guided, accelerated iTBS produces significant reductions in depression severity, and to what extent this benefit extends to ultra treatment-resistant depression (UTRD). Design: This was an open-label feasibility trial of connectivity-guided, accelerated iTBS in patients with TRD. Two distinct groups of participants were recruited from a neurosurgical-psychiatry clinic with UTRD and an interventional psychiatry clinic with TRD. Patients were stratified into a priori treatment-resistance subgroups. Patients received five days of open-label treatment. Outcome measures were collected immediately prior to and after treatment, as well as at 4- and 12-weeks post-treatment. Setting: This trial ( NCT05813093 ) was conducted between November 2023 and July 2025 at Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada. Participants: Patients with major depressive disorder. A total of 96 participants were screened, with 73 meeting eligibility criteria (UTRD=30, TRD=43). One withdrew due to inability to tolerate the baseline MRI, and the other withdrew voluntarily prior to treatment. Intervention: Participants underwent a neuronavigated accelerated iTBS (600 pulses) protocol using personalized left dorsolateral prefrontal cortex (dlPFC) targets derived from functional magnetic resonance imaging (fMRI), comprising eight daily treatments, repeated over five days. Main Outcomes: Primary outcomes were i) change in Hamilton Depression Rating Scale (HAM-D17) from baseline to the end of the fifth day of treatment, and ii) the difference in change in HAM-D17 between UTRD and TRD subgroups. Results: Connectivity-guided fMRI targeting yielded personalized targets clustered around the anterolateral dlPFC. Accelerated iTBS elicited rapid antidepressant effects (ΔHAM-D17 -9.01 [SD 6.06], t = -12.45, p < 0.001) regardless of treatment-resistance group (ΔHAM-D17 -9.64 [SD 5.94] vs -8.10 [SD 6.12], t = -1.05, p = 0.299), which were sustained up to 12 weeks after treatment. Overall response and remission rates at the end of treatment were 40.8% and 16.9%. Self-report scales revealed broad symptomatic relief outside of core depressive symptoms. Conclusions & Relevance: This study demonstrated that fMRI connectivity-guided, accelerated iTBS induces sustained antidepressant effects and broader psychiatric benefits in patients across the spectrum of TRD. In a cohort unlikely to respond to most antidepressant therapies, connectivity-guided, accelerated iTBS offers a safe, well-tolerated option that can achieve benefit, or when ineffective, allow patients to expeditiously proceed with subsequent therapies than conventional rTMS. Trial Registration: This clinical trial was registered at clinicaltrials.gov with NCT05813093 .
- Open Access
- 17 November 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1)
Objective speech measures capture depressive symptoms and associated cognitive difficulties
Psychiatry lacks objective biomarkers for assessing depression, relying instead on subjective measures, such as the Hamilton Depression Rating Scale (HAMD-17). This study examined whether speech features could serve as objective markers of depressive symptoms and its associated cognitive difficulties. Sixty-six individuals with major depressive disorder (MDD) and 54 non-depressed control participants completed a speech assessment, responding to the prompt: “Please tell me how you are feeling today.” Linguistic (valence, emotional intensity, agency) and acoustic (pitch, pitch variance, speech rate, time spent pausing) features were derived from natural language processing. These speech features were analyzed individually and collectively as a composite score representing overall speech disturbance. A subset of participants (40 with MDD, 38 controls) also completed a validated executive function task. ANCOVA models compared speech features between groups. Linear regression models examined associations between speech features, depression severity (HAMD-17), and performance on an executive function task. Compared to controls, individuals with MDD used language that was more negatively valenced, emotionally intense, and less agentic. They also demonstrated lower pitch, slower speech rate, and more time spent pausing. The composite speech score also differed between groups. Speech features and executive function were not associated with depression severity, as measured by the HAMD-17. However, several speech features were associated with executive function. Taken together, these findings suggest that speech features may provide a scalable, objective method for detecting depressive symptoms and associated executive difficulties.
- 17 November 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1)
Open AccessObjective speech measures capture depressive symptoms and associated cognitive difficulties
Psychiatry lacks objective biomarkers for assessing depression, relying instead on subjective measures, such as the Hamilton Depression Rating Scale (HAMD-17). This study examined whether speech features could serve as objective markers of depressive symptoms and its associated cognitive difficulties. Sixty-six individuals with major depressive disorder (MDD) and 54 non-depressed control participants completed a speech assessment, responding to the prompt: “Please tell me how you are feeling today.” Linguistic (valence, emotional intensity, agency) and acoustic (pitch, pitch variance, speech rate, time spent pausing) features were derived from natural language processing. These speech features were analyzed individually and collectively as a composite score representing overall speech disturbance. A subset of participants (40 with MDD, 38 controls) also completed a validated executive function task. ANCOVA models compared speech features between groups. Linear regression models examined associations between speech features, depression severity (HAMD-17), and performance on an executive function task. Compared to controls, individuals with MDD used language that was more negatively valenced, emotionally intense, and less agentic. They also demonstrated lower pitch, slower speech rate, and more time spent pausing. The composite speech score also differed between groups. Speech features and executive function were not associated with depression severity, as measured by the HAMD-17. However, several speech features were associated with executive function. Taken together, these findings suggest that speech features may provide a scalable, objective method for detecting depressive symptoms and associated executive difficulties.
- Open Access
- 11 June 2025
- Published by Springer Nature in Research Square
Speech as an Objective Marker of Depression and Associated Cognitive Difficulties
Psychiatry lacks objective biomarkers for assessing depression. Instead, symptoms are measured using self- and clinician-reported measures, with the Hamilton Depression Rating Scale (HAMD-17) widely regarded as the gold standard. However, traditional assessments like the HAMD-17 often fail to capture all aspects of depression, particularly cognitive difficulties. This study examined whether speech features could serve as objective markers of depressive symptoms, including cognitive difficulties. Sixty-six individuals with depression and 54 non-depressed control participants completed a speech assessment, responding to the prompt: “Please tell me how you are feeling today.” Linguistic (valence, emotional intensity, agency) and acoustic (pitch, pitch variance, speech rate, pause duration) features were derived from natural language processing. Features were analyzed both individually and as a composite score. A subset of participants (N = 59) also completed an eye-tracking task assessing executive function. ANCOVAs compared speech features between groups, and linear regression models examined the associations between speech features, depression severity (HAMD-17), and executive function performance. Compared to control participants, individuals with depression used language that was significantly more negatively valenced, emotionally intense, and lower in agency. They also exhibited significantly lower pitch, slower speech rate, more pauses, and differed in the composite score. However, speech features were not significantly associated with depression severity. While depression severity was not associated with executive function performance, several speech features were, including negative valence, emotional intensity, agency, pause duration, and the composite score. These findings suggest that speech features may offer an accessible, objective method for assessing both depression and associated cognitive difficulties.
- 11 June 2025
- Published by Springer Nature in Research Square
Open AccessSpeech as an Objective Marker of Depression and Associated Cognitive Difficulties
Psychiatry lacks objective biomarkers for assessing depression. Instead, symptoms are measured using self- and clinician-reported measures, with the Hamilton Depression Rating Scale (HAMD-17) widely regarded as the gold standard. However, traditional assessments like the HAMD-17 often fail to capture all aspects of depression, particularly cognitive difficulties. This study examined whether speech features could serve as objective markers of depressive symptoms, including cognitive difficulties. Sixty-six individuals with depression and 54 non-depressed control participants completed a speech assessment, responding to the prompt: “Please tell me how you are feeling today.” Linguistic (valence, emotional intensity, agency) and acoustic (pitch, pitch variance, speech rate, pause duration) features were derived from natural language processing. Features were analyzed both individually and as a composite score. A subset of participants (N = 59) also completed an eye-tracking task assessing executive function. ANCOVAs compared speech features between groups, and linear regression models examined the associations between speech features, depression severity (HAMD-17), and executive function performance. Compared to control participants, individuals with depression used language that was significantly more negatively valenced, emotionally intense, and lower in agency. They also exhibited significantly lower pitch, slower speech rate, more pauses, and differed in the composite score. However, speech features were not significantly associated with depression severity. While depression severity was not associated with executive function performance, several speech features were, including negative valence, emotional intensity, agency, pause duration, and the composite score. These findings suggest that speech features may offer an accessible, objective method for assessing both depression and associated cognitive difficulties.
- Open Access
- 16 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (20) , eadp0532
Optimal focused ultrasound lesion location in essential tremor
Magnetic resonance–guided focused ultrasound (MRgFUS) thalamotomy is an effective treatment for medically refractory essential tremor. We investigate ablation sites and potential tracts associated with optimal tremor control and side effects based on the analysis of 351 cases from three international hospitals. Lesions were segmented on day 1 thin-cut T2 axial images, mapped to standard Montreal Neurological Institute space, and used to derive probabilistic maps and tracts associated with tremor improvement and side effects. Lesioning of a specific subregion within the ventral intermediate nucleus and the cerebellothalamic tract was associated with optimal tremor improvements. Some lesion locations and tracts were associated with differential side effects. Overlaps with the optimal tremor improvement sites accounted for variance in clinical improvements in out-of-sample cases. Efficacy of this location was further confirmed by test-retest cases that underwent two MRgFUS procedures. We identify and validate a target area for optimal tremor control and sites of avoidance associated with side effects.
- 16 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (20) , eadp0532
Open AccessOptimal focused ultrasound lesion location in essential tremor
Magnetic resonance–guided focused ultrasound (MRgFUS) thalamotomy is an effective treatment for medically refractory essential tremor. We investigate ablation sites and potential tracts associated with optimal tremor control and side effects based on the analysis of 351 cases from three international hospitals. Lesions were segmented on day 1 thin-cut T2 axial images, mapped to standard Montreal Neurological Institute space, and used to derive probabilistic maps and tracts associated with tremor improvement and side effects. Lesioning of a specific subregion within the ventral intermediate nucleus and the cerebellothalamic tract was associated with optimal tremor improvements. Some lesion locations and tracts were associated with differential side effects. Overlaps with the optimal tremor improvement sites accounted for variance in clinical improvements in out-of-sample cases. Efficacy of this location was further confirmed by test-retest cases that underwent two MRgFUS procedures. We identify and validate a target area for optimal tremor control and sites of avoidance associated with side effects.
- 16 November 2024
- Published by Springer Nature
- p. 187-206
Neuroethics